-
1 week ago | 
ophthalmologytimes.com | Deep Parikh |Emily Kaiser Maharjan
Author(s):,Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease. Editor's note: The below transcript has been lightly edited for clarity. Hi everyone. I'm here with Dr Deep Parikh, who is presenting at the Collaborative Care Symposium on advanced treatments in neovascular retinal disease. Thank you so much for being here, Dr Parikh.
-
1 week ago | 
optometrytimes.com | Mitch Ibach |Emily Kaiser Maharjan |Jordana Joy
During his presentation titled "Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition," Mitch Ibach, OD, FAAO, discussed the prevalence of dry eye disease, a significant ocular condition affecting approximately 18 million patients in the United States - 4 times more than those diagnosed with open-angle glaucoma. Ibach emphasized the growing patient awareness and motivation surrounding dry eye, which distinguishes it from other eye conditions like glaucoma.
-
1 week ago | 
optometrytimes.com | Emily Kaiser Maharjan |Martin Harp
Alcon announced that the FDA has approved acoltremon ophthalmic solution 0.003%, a first-in-class transient receptor potential melastatin 8 (TRPM8) receptor agonist, for the treatment of the signs and symptoms of dry eye disease (DED). The drop, previously known as AR-15512, will be sold under the name Tryptyr.
-
1 week ago | 
ophthalmologytimes.com | Hattie Hayes |Emily Kaiser Maharjan
Robert Maloney, MD, cofounder of the Maloney-Shamie-Hura Vision Institute, announced he has retired from his surgical practice. Dr. Maloney recently completed a six-month sabbatical at Oxford University, during which he researched Harold Ridley, Stewart Duke-Elder, and the development of the intraocular lens.
-
1 week ago | 
optometrytimes.com | John Gelles |Steven Greenstein |Emily Kaiser Maharjan
May 28, 2025By In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.Since its inception in 2021, the Collaborative Care Symposium has helped eye care providers bridge the gap between optometry and ophthalmology. Cochaired by John D.
-
1 week ago | 
optometrytimes.com | Bridgitte Shen Lee |Emily Kaiser Maharjan |Jordana Joy
May 28, 2025By Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025. In detailing a poster presentation given on perfluorohexyloctane (PFHO) (Miebo) on a dry eye disease treatment, Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, highlighted 2 key takeaways from the research. The first takeaway emphasizes the study's robust methodology.
-
1 week ago | 
optometrytimes.com | Bridgitte Shen Lee |Emily Kaiser Maharjan |Jordana Joy
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, presented a poster at ARVO 2025 discussing the early adoption and utilization of perfluorohexoloctane (Miebo), a new medication for dry eye disease. This medication is unique as the first of its kind in the prescription dry eye treatment market, which currently includes 7 FDA-approved medications. The research utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
-
1 week ago | 
ophthalmologytimes.com | Steven Greenstein |John Gelles |Emily Kaiser Maharjan
Since its inception in 2021, the Collaborative Care Symposium has helped eye care providers bridge the gap between optometry and ophthalmology. Cochaired by John D. Gelles, OD, and Steven Greenstein, MD, the symposium offers a unique, free, and entirely virtual platform designed to foster deeper collaboration and practical learning across the eye care spectrum.
-
2 weeks ago | 
ophthalmologytimes.com | Steven Greenstein |Emily Kaiser Maharjan
Author(s):,Fact checked by:Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect. Editor's note: The below transcript has been lightly edited for clarity. Hi everyone. I'm here with Dr Steven Greenstein, one of the cochairs of the Collaborative Care Symposium, and he's going to tell us a little bit about the meeting, which offers CE and some practical pearls on all aspects of refractive surgery.
-
2 weeks ago | 
ophthalmologytimes.com | Martin Harp |Emily Kaiser Maharjan
The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months, according to the company.
